We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biotronik has announced the first worldwide implantation of a Philos II DR-T
pacemaker and a Lexos DR-T ICD with advanced Home Monitoring Early Detection
technology.
Springfield, Mass.-based firearms company Smith & Wesson launched its new,
second-generation automated external defibrillator (AED), the Smith & Wesson
Heartbeat AED. The new Smith & Wesson Heartbeat AED uses the "1-2-3"
rescue approach, in which text messages and voice prompts walk the nonmedical
user through the procedure.
Neothermia has reached an agreement with Rubicor
Medical for the dismissal of patent infringement and breach of contract litigation
filed against Rubicor by Neothermia.
FlowCardia, a developer of catheter-based systems to treat chronic total occlusions
(CTOs) of coronary and peripheral arteries, has announced that the company's
application for CE Marking of the CROSSER catheter has been approved for use
in coronary arteries following failure to cross CTOs with conventional guidewire
techniques.
Edwards Lifesciences has received conditional approval from the FDA to begin
the first feasibility trial of its Cribier-Edwards percutaneous aortic heart
valve.
Medicare officials say roughly 500,000 Medicare beneficiaries can now receive
coverage for expensive implantable cardioverter defibrillators - if they agree
to release details about their cases to a database shared by hospitals.
IMI International Medical Innovations has announced that PREVU Point of Care
Skin Sterol Test, a noninvasive, predictive test for coronary artery disease,
is now available for sale in Canada and the U.S. PREVU, which measures the amount
of cholesterol, or sterol, accumulated in the skin tissues, is marketed and
distributed worldwide by McNeil Consumer Healthcare.
iCAD, which designs, develops and markets Computer Aided Detection (CAD) imaging
technology and systems for the early detection of breast cancer and other medical
applications, has released its Second Look 700 CAD solution.